We serve Chemical Name:2-amino-N-propylbenzamide CAS:56814-10-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-amino-N-propylbenzamide
CAS.NO:56814-10-9
Synonyms:N-propyl-2-aminobenzoic amide;anthranilic acid propylamide;2-amino-N-propyl-benzamide;N-propyl anthranylamide;F3034-0134
Molecular Formula:C10H14N2O
Molecular Weight:178.23100
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:363.7ºC at 760 mmHg
Density:1.079g/cm3
Index of Refraction:1.56
PSA:55.12000
Exact Mass:178.11100
LogP:2.38070
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-propyl-2-aminobenzoic amide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,F3034-0134 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,anthranilic acid propylamide Use and application,2-amino-N-propyl-benzamide technical grade,usp/ep/jp grade.
Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 2-amino-N-propylbenzamide manufacturer Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 2-amino-N-propylbenzamide supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 2-amino-N-propylbenzamide vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 2-amino-N-propylbenzamide factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
